Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Sufentanil Stories

2012-04-12 02:38:11

REDWOOD CITY, Calif., April 12, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported dosing of the first patient in the second of three planned Phase 3 studies that will form the basis of a planned New Drug Application (NDA) for the Sufentanil NanoTab® PCA System, ARX-01. Utilizing a...

2012-04-11 02:24:34

REDWOOD CITY, Calif., April 11, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the U.S. Patent and Trademark Office (USPTO) has issued AcelRx two Notices of Allowance for the patent applications entitled "Small-Volume Oral Transmucosal Dosage Forms" and "Bioadhesive Drug Formulations for Oral Transmucosal...

2012-03-20 02:24:07

REDWOOD CITY, Calif., March 20, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the fourth quarter and year ended December 31, 2011. Net loss for the fourth quarter of 2011 was $6.4 million, or $0.33 per share, compared with a net loss of $3.5 million, or $5.23 per...

2012-03-06 18:39:00

REDWOOD CITY, Calif., March 6, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, reported dosing of the first patient in a Phase 3 study for ARX-01, the Sufentanil NanoTab PCA System, its novel sublingual patient-controlled analgesia system. This first ARX-01 Phase 3 study is a randomized,...

2012-03-01 15:05:00

CUPERTINO, Calif., March 1, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2011. Total revenues were $8.9 million for the three months ended December 31, 2011, up from $8.5 million for the three months ended December 31, 2010. Net loss for the three months ended December 31, 2011 was $2.1 million, down from a net loss of $5.3 million for the same period in 2010. (Logo:...

2012-02-24 08:00:00

CUPERTINO, Calif., Feb. 24, 2012 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2011 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, March 1, 2012 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) A live audio webcast of the presentation will be available by accessing DURECT's homepage at...

2012-02-21 06:30:00

REDWOOD CITY, Calif., Feb. 21, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and Chief Executive Officer, will present at two separate investor conferences, one in New York City, NY and one in Boston, MA, over the coming weeks as follows: Citi 2012 Global Health...

2012-02-07 11:03:00

CUPERTINO, Calif., Feb. 7, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan (Chief Financial Officer) will be presenting at the BIO CEO & Investor Conference on Tuesday, February 14 at 10:30 a.m. Eastern Time. The conference is being held at the Waldorf-Astoria Hotel in New York City. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) A live audio webcast of the presentation will be available by accessing...

2012-01-31 06:30:00

REDWOOD CITY, Calif., Jan. 31, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, reported that the two remaining items required by the FDA prior to the initiation of the Phase 3 clinical program for ARX-01, specifically software verification and validation of the ARX-01 system, are progressing....

2012-01-30 15:15:00

CUPERTINO, Calif., Jan. 30, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today reported that Takeda (through Nycomed) has given notice that it is returning its development and commercialization rights to POSIDUR(TM) (SABER(TM)-Bupivacaine) in Europe and their other licensed territories. Takeda acquired its rights to POSIDUR through its acquisition of Nycomed in September, 2011. POSIDUR is a post-operative pain relief depot that utilizes DURECT's patented SABER(TM)...